We have located links that may give you full text access.
Changes to Corneal Aberrations and Vision After Monovision in Patients With Hyperopia After Using a Customized Aspheric Ablation Profile to Increase Corneal Asphericity (Q-factor).
Journal of Refractive Surgery 2016 November 2
PURPOSE: To evaluate the visual outcomes and fourth-order Zernike spherical aberrations induced with a customized change in corneal asphericity (ΔQ) correction of presbyopia combined with monovision for hyperopic patients.
METHODS: Consecutive hyperopic patients who underwent presbyopic LASIK between September 2013 and July 2014 were included. For the non-dominant eyes, the aspheric ablation profile associated with a myopic refraction was planned using the Custom-Q nomogram (Alcon Laboratories, Inc., Fort Worth, TX). Uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), spherical equivalent refraction, ΔQ, and change in corneal spherical aberration coefficient (ΔC4 0 ) were analyzed. Postoperative data were collected at 1, 3, and 6 months.
RESULTS: Sixty-five patients were included. The mean age was 56.5 ± 5.7 years (range: 47 to 70 years). At the 6-month follow-up, the spherical equivalent refraction for non-dominant and dominant eyes was -1.07 ± 0.74 and 0.32 ± 0.55 diopters (D), respectively. The mean binocular UDVA was 0.01 ± 0.04 logMAR (range: -0.12 to 0.30 logMAR); 91% of patients achieved 20/20 or better binocular UDVA and 83% of patients had Jaeger 3 (Parinaud 4) or better binocular UNVA. The ΔQ for non-dominant and dominant eyes was -0.61 ± 0.15 and -0.33 ± 0.25, respectively, for a 6-mm pupil diameter and was significantly higher for non-dominant eyes (P < .0001). The achieved ΔC4 0 was -0.49 ± 0.23 µm for non-dominant eyes (for a theoretical ideal value of -0.40 µm) and -0.30 ± 0.18 µm for dominant eyes. For non-dominant eyes, the attempted ΔQ (-0.60) was close to the achieved value (-0.61 ± 0.15).
CONCLUSIONS: For hyperopic patients, combining the customized corneal aspheric ablation profile with monovision is safe, effective, and reproducible, inducing intended changes in corneal spherical aberrations. [J Refract Surg. 2016;32(11):734-741.].
METHODS: Consecutive hyperopic patients who underwent presbyopic LASIK between September 2013 and July 2014 were included. For the non-dominant eyes, the aspheric ablation profile associated with a myopic refraction was planned using the Custom-Q nomogram (Alcon Laboratories, Inc., Fort Worth, TX). Uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), spherical equivalent refraction, ΔQ, and change in corneal spherical aberration coefficient (ΔC4 0 ) were analyzed. Postoperative data were collected at 1, 3, and 6 months.
RESULTS: Sixty-five patients were included. The mean age was 56.5 ± 5.7 years (range: 47 to 70 years). At the 6-month follow-up, the spherical equivalent refraction for non-dominant and dominant eyes was -1.07 ± 0.74 and 0.32 ± 0.55 diopters (D), respectively. The mean binocular UDVA was 0.01 ± 0.04 logMAR (range: -0.12 to 0.30 logMAR); 91% of patients achieved 20/20 or better binocular UDVA and 83% of patients had Jaeger 3 (Parinaud 4) or better binocular UNVA. The ΔQ for non-dominant and dominant eyes was -0.61 ± 0.15 and -0.33 ± 0.25, respectively, for a 6-mm pupil diameter and was significantly higher for non-dominant eyes (P < .0001). The achieved ΔC4 0 was -0.49 ± 0.23 µm for non-dominant eyes (for a theoretical ideal value of -0.40 µm) and -0.30 ± 0.18 µm for dominant eyes. For non-dominant eyes, the attempted ΔQ (-0.60) was close to the achieved value (-0.61 ± 0.15).
CONCLUSIONS: For hyperopic patients, combining the customized corneal aspheric ablation profile with monovision is safe, effective, and reproducible, inducing intended changes in corneal spherical aberrations. [J Refract Surg. 2016;32(11):734-741.].
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app